Brief: Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301
06/08/2025 13:53
Aug 6 (Reuters) - Cingulate Inc CING.O: CINGULATE SUBMITS NEW DRUG APPLICATION TO FDA FOR LEAD ADHD ASSET CTX-1301 Source text: ID:nGNX9YPd9c Further company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)